Efficacy of cefminox in the treatment of bacterial infections.

Abstract

In an open trial, 1841 patients were treated with mainly 1 g of cefminox twice a day in adults or 20-30 mg/kg three or four times a day in children for up to 14 days. The clinical efficacy was assessed in 1560 patients (1256 adults, 304 children) and the efficacy rates were as follows: 82.3% in respiratory tract infections (n:525), 85.7% in biliary tract infections (n:87), 66.4% in urinary tract infections (n:509), 92.1% in gynaecological infections (n:126), 88.1% in peritonitis (n:84), 74.9% in all infections (n:1560). The overall bacterial response rates in single infections were 81.5% (81.5% for Staphylococcus aureus, 98.4% for Escherichia coli, 98.6% for Haemophilia influenzae and 38.8% for Pseudomonas aeruginosa). The safety of cefminox was assessed in 1831 patients. Adverse side-effects were reported in 35 patients (1.9%), the most frequent being rash.

• Authors: S Omoto, S Watanabe
• Journal: International journal of clinical pharmacology research (Int J Clin Pharmacol Res) Vol. 10 Issue 6 Pg. 361-8 ( 1990) ISSN: 0251-1649 [Print] Switzerland
• PMID: 2099361 (Publication Type: Journal Article)

Chemical References

• Cephamycins
• Sodium Hypochlorite
• cefminox

Topics

• Bacterial Infections (drug therapy, microbiology)
• Cephamycins (adverse effects, pharmacokinetics, therapeutic use)
• Female
• Humans
• Infusions, Intravenous
• Injections, Intravenous
• Male
• Sodium Hypochlorite
• Tissue Distribution